CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) said yesterday that it will receive $60 million in funding over the next two years from global charitable foundation Wellcome.
The award from Wellcome, which co-founded CARB-X in 2016 and has supported it over the past decade, will help the public-private partnership continue its efforts to support early-stage development of innovative new antibiotics, preventatives, alternative treatments, and rapid diagnostics for the most challenging drug-resistant bacteria. CARB-X typically funds products that have shown promise in pre-clinical studies, with the aim of shepherding those products into phase 1 studies in people.
Since 2016, CARB-X has supported 121 research-and-development projects in 15 countries, 24 of which have advanced into or completed clinical trials. Three CARB-X–funded projects have reached the market.
Focus on infections in low-resource countries
Wellcome officials hailed CARB-X’s focus on products that address high-burden infections in low- and middle-income countries, including lower respiratory tract infections, bloodstream infections, and sexually transmitted infections.
“By integrating funding with technical expertise, CARB-X can accelerate innovation to progress ambitious science from the lab to the clinic, ensuring new tools are accessible to those in greatest need—protecting and saving lives globally,” Alex Pym, MBBS, PhD, director of infectious diseases at Wellcome, said in a CARB-X press release.
CARB-X Executive Director Kevin Outterson, JD, called the renewed partnership with Wellcome a “powerful vote of confidence.”
“Together, we are building a pipeline that delivers innovative products responsibly, ensuring they are used wisely and reach the people who need them,” Outterson said.